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1. Introduction
Protein phosphorylation/dephosphorylation is an 
indispensable post-translational regulatory mechanism in a wide 
range of cellular processes.1 Numerous chemical tools have been 
developed for controlling or monitoring phosphorylation and/or 
dephosphorylation events, enabling clarification of their 
biological significance.2 A caged phosphopeptide is a useful tool 
for spatiotemporal regulation of phosphopeptide biological 
activity (Scheme 1).3 Caged peptide 1 has a photo-removable 
protective group on a phosphate moiety to mask its key 
functionality. Its biological activity derived from interaction 
between the phosphate and a target biomolecule is therefore 
turned off. On photo-irradiation followed by removal of the 
protective group, the biologically active parent phosphopeptide 2 
is generated. Although this technique is useful in the study of 
phosphorylation/dephosphorylation events, there is a risk of 
conversion of the active phosphopeptide 2 to an inactive form by 
hydrolysis of the phosphate by endogenous phosphatases. It is 
therefore desirable to avoid removal of the phosphate of 
phosphopeptides. 
Scheme 1. Caged phosphopeptide (PG: protective group removable by 
photo-irradiation) 
We and other groups have already developed non-
hydrolyzable phosphopeptides in which an oxygen of a 
phosphoester moiety has been replaced by a difluoromethylene 
(CF2) unit to prevent phosphate hydrolysis (Scheme 2).4–6 
Because the physical properties of difluoromethyl phosphonates 
are similar to those of the corresponding phosphates (e.g., pKa2, 
charge under physiological conditions, and bond angle of C–X–P 
in H2NCH2XPO3H2: 5.6, –2, and 117˚, respectively, for CF2 
derivative, X is CF2; 6.5, –2, and 119˚, respectively, for the 
monoalkyl phosphate, X is oxygen),7 they can be successfully 
used to elucidate the biological functions of phosphorylated 
peptides and proteins.8,9 We therefore designed a caged non-
hydrolyzable phosphopeptide that should work as a caged 
phosphopeptide mimetic without enzymatic hydrolysis of the 
phosphate.10 Although introduction of two photo-responsive 
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protective groups into the phosphonate is possible, 
monoprotection was used in this study because the bulkiness of 
the group was expected to be enough to prevent binding of the 
caged peptide to the phosphate-recognizing pockets of proteins. 
The mono-protected phosphonate was presumed to be compatible 
with solid-phase peptide synthesis (SPPS) because amino acid 
building blocks containing the mono-protected phosphate or non-
protected phosphonate have been employed for preparation of 
phosphopeptides and their analogs.11 In this paper, the synthesis 
and photoreactions of phosphopeptide mimetics with caged non-
hydrolyzable phospho-serine, -threonine, and -tyrosine are 
described. Application of the serine derivative to photo-control of 
binding affinity to 14-3-3β protein is also reported. 
 
 
Scheme 2. Design of caged non-hydrolyzable phosphopeptide (PG: 
protective group removable by photo-irradiation) 
 
2. Results and discussion 
2.1. Synthesis of caged non-hydrolyzable phosphoamino acid 
derivatives and their incorporation into peptides 
Fmoc-protected non-hydrolyzable phosphoserine 3a 
containing a photo-removable protection was first synthesized as 
shown in Scheme 3. In this study, an o-nitrobenzyl (oNB) group 
was chosen as the photo-responsive protective group because of 
its widespread use in a chemical biology field, simple structure 
without a chiral center and commercial availability.3a,12 
Carboxylic acid 4a4a was treated with allyl bromide in the 
presence of K2CO3 to afford ester 5a. The Boc group of 5a was 
replaced by an Fmoc group to give 6a. The ethyl groups of 6a 
were removed by treatment with TMSBr in CH2Cl2 followed by 
aqueous MeCN. Monoesterification of phosphonate 7a was then 
achieved by the use of a p-toluenesulfonyl chloride (TsCl)-
pyridine system. Compound 8a was used for a subsequent 
reaction without hesitation because of its insctability. Finally, the 
allyl group of 8a was removed in the presence of palladium(0) to 
generate Fmoc-protected non-hydrolyzable phosphoserine 3a. 
Purification of the product was highly complicated because of its 
high polarity, so crude 3a without column chromatography 
purification was used in subsequent reactions.13 
To examine the photo-reactivity and photo-control of the 
binding affinity of the phosphoserine mimetic-containing peptide, 
serine derivative 3a was then incorporated into a model peptide. 
In this study, a ligand analog of a 14-3-3β protein14 was 
synthesized because a phosphate moiety on the ligand is critical 
for binding15,16 and the ligand sequence has been well studied.17 
The caged phosphopeptide mimetic 9a, in which a phosphoserine 
of the original sequence was replaced by the caged non-
hydrolyzable derivative, was prepared using standard Fmoc SPPS. 
For the coupling reaction, O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HBTU) and N,N-
diisopropylethylamine (DIEA) were used before introduction of 
serine derivative 3a, whereas 2-(1H-7-azabenzotriaol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 1-
hydroxyl-7-azabenzotriazole (HOAt), and DIEA were used for 
introduction of 3a. An HBTU/DIEA system was used for further 
chain elongation.18 After introduction of an 8-amino-3,6-
dioxaoctanoyl (miniPEG) linker, a 5-
fluoresceinylaminothiocarbonyl (FTC) group was incorporated 
by treatment with 5-fluorescein isothiocyanate (FITC) in the 
presence of DIEA for the subsequent fluorescence-based binding 
assay. 
Fmoc-protected threonine derivative 3b and tyrosine 
derivative 3c were also prepared, starting from 4b5a,19 or 4c6a, 
similarly to the serine derivative 3a except for the introduction of 
the oNB group on 7b. When 7b was treated with TsCl and 
pyridine, the yield of monoester 8b was not sufficient but a mass 
spectrometric analysis of the crude reaction mixture gave a main 
peak identical to [7b – H2O – H]– (data not shown). We thought 
that dehydrative cyclization took place via electrophilic 
activation of the phosphonate by TsCl, therefore, o-NB bromide 
was employed to avoid the cyclization induced by TsCl. Crude 
3b and 3c, without column chromatography purification, were 




Scheme 3. Synthesis of caged non-hydrolyzable phosphoamino acid 
derivatives (oNB: o-nitrobenzyl). Reagents and conditions: a) allyl bromide, 
K2CO3 for 5a and 5c or Na2CO3 for 5b, DMF, 97% (5a), 98% (5b), 85% (5c); 
b) TFA; c) N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide (FmocOSu), 
MeCN, 10% (w/v) Na2CO3 aq, 60% (6a), 97% (6b), 77% (6c) (two steps); d) 
TMSBr, CH2Cl2, then MeCN aq, 97% (7a), 81% (7b), 51% (7c); e) oNB 
alcohol, TsCl, pyridine, DMF for 8a and 8c, or oNB bromide, DIEA, DMF, 
50 ˚C for 8b, 68% (8a), 84% (8b), 54% (8c); f) (Ph3P)4Pd, N-methylaniline, 
3 
 
THF; g) Fmoc SPPS using HBTU/DIEA or HATU/HOAt/DIEA system (A: 




Figure 1. Photo-irradiation reactions. (A) Reagents and conditions: method (a) UV-irradiation (>365 nm, 7 min) in sodium phosphate buffer (10 mM, pH 7.6); 
method (b) UV irradiation (>365 nm, 7 min) in 0.1% (v/v) aqueous solution of TFA. (B)–(E) Analytical HPLC profiles of reaction of peptide 9a (B: method a; C: 
method b), 9b (D: method a), and 9c (E: method a), before and after UV irradiation. *Non-peptidyl peaks. HPLC conditions: linear gradient of 0.1% (v/v) 
TFA/MeCN in 0.1% (v/v) TFA aq, 10–45% (B, C) or 5–45% (D, E) over 30 min. 
 
2.2.  UV-induced generation of non-hydrolyzable 
phosphopeptides 
Next, UV-irradiation experiments were performed on caged 
peptide 9a possessing the serine derivative (Figure 1A and 1B). 
Caged peptide 9a in sodium phosphate buffer (pH 7.6) was 
subjected to UV irradiation (>365 nm). HPLC analysis showed 
that 9a completely disappeared within 7 min on UV irradiation. 
The observed mass of the product, however, did not correspond 
to [10a + H]+ but to [10a + H – 16]+. The structure of the product 
was assumed to be 10a’ in which a sulfur atom of the 
thiocarbonyl moiety of 10a was replaced by oxygen, presumably 
as a result of reaction with singlet oxygen generated via photo-
sensitization by the FTC group.20 Although the conversion of 10a 
to 10a’ was not thought to be problematic for biological 
applications,20c the uncaging reaction was also examined under 
acidic conditions because the absorption coefficient of a 
fluorescein under acidic conditions is smaller than that under 
neutral conditions [0.1% (v/v) TFA in H2O, pH 1.9; Figure 1C].21 
In this case, uncaged peptide 10a instead of 10a’ was obtained in 
high conversion yield. UV-irradiation experiments were also 
performed on threonine derivative 9b and tyrosine derivative 9c 
in phosphate buffer (pH 7.6), and high-purity uncaged 
phosphopeptide mimetics 10b and 10c were generated (Figure 
1D and 1E). These results encouraged us to examine whether 
photo-uncaging of the caged non-hydrolyzable phosphopeptide 
can control interactions with phosphopeptide-binding proteins. 
2.3. Photo-control of phosphopeptide mimetics-protein 
interaction 
Binding of the caged non-hydrolyzable phosphoserine 
derivative 9a to 14-3-3β protein was examined (Figure 2). In this 
study, ΔmP values [ΔmP = (FP in the presence of 14-3-3β) – (FP 
in the absence of 14-3-3β), where FP is the fluorescence 
polarization signal in mP (milli-polarization units)] before and 
after UV irradiation were compared. If the peptide can bind to 
14-3-3β protein, the FP increases on addition of the protein. The 
ΔmP value should therefore be positive. When 14-3-3β was 
added to a solution of caged peptide 9a in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (pH 7.4),22 ΔmP 
was close to zero, similar to that for the negative control 11 (9a: 
–0.2 ± 3.6 mP; 11: 5.2 ± 0.7 mP). In contrast, large ΔmP values 
were observed in the case of UV-irradiated 9a (>365 nm, 7 
min)23 and positive control 10a (UV-irradiated 9a: 18.9 ± 1.6 mP; 
10a: 39.4 ± 1.5 mP) compared with those for 9a without UV 
irradiation and negative control 11, respectively. Reason for a 
difference of ΔmP values of 9a (UV+) and 10a is not clear at 
present. However, in these experiments, the point is that the ΔmP 
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value of 9a was increased by the UV irradiation. It was therefore 
demonstrated that binding of the non-hydrolyzable 
phosphopeptide to 14-3-3β was controlled by UV irradiation. 
 
 
Figure 2. Binding assay based on FP. (A) Structures of caged non-
hydrolyzable peptide and reference peptides and (B) binding assays of 
peptides to 14-3-3β. The peptide (20 nM, final) in HEPES buffer [10 mM 
HEPES, 150 mM NaCl, 0.05% (w/v) Tween-20, 0.5 mM dithiothreitol, pH 
7.4] was incubated at 20 ˚C in the absence or presence of 14-3-3β (500 nM, 
final) for 1 h.22 The FP signals were recorded in mP (milli-polarization units), 
and the ΔmP values were calculated as follows. ΔmP = (FP in the presence of 
14-3-3β) – (FP in the absence of 14-3-3β). Averages of nine measurements 
are shown with the standard error of the mean. A statistical analysis was 
performed using the t test (*p<0.005). 9a (UV+): UV (>365 nm) was 
irradiated to 9a in the HEPES buffer for 7 min before the FP experiments. (C) 
HPLC monitoring of preparation of 9a (UV+) for subsequent binding assay. 
HPLC charts before and after UV irradiation to caged peptide 9a in HEPES 
buffer are depicted. Reaction conditions are shown above and in the 
experimental section. Analytical HPLC conditions: linear gradient of 0.1% 
(v/v) TFA/MeCN in 0.1% (v/v) TFA aq, 10 to 45% over 30 min. 
 
3. Conclusion 
Caged non-hydrolyzable phosphoserine, phosphothreonine, 
and phosphotyrosine derivatives were synthesized and 
incorporated into peptides using standard Fmoc SPPS. UV-
induced deprotection of the caged peptides generated the parent 
non-hydrolyzable phosphopeptide mimetics in high purity. The 
binding assay of the non-hydrolyzable phosphoserine-containing 
peptide to 14-3-3β protein was also examined, and the affinity 
was successfully controlled by UV irradiation. Applications of 
the caged non-hydrolyzable phosphopeptide mimetics to tools for 
photo-control the phosphopeptide-protein interaction events are 
being investigated. 
4. Experimental Section 
4.1. General Methods 
All reactions of small molecules were carried out under a 
positive pressure of argon. For column chromatography, Silica 
Gel 60 N (spherical, neutral, Kanto Chemical Co.,Inc.) was 
employed. NMR spectra were recorded for 1H and 31P (proton 
decoupled) and 13C (signals of difluoromethylene units 
sometimes were not detected). For HPLC separations, a Cosmosil 
5C18-AR-II analytical column (Nacalai Tesque, 4.6 × 250 mm, 
flow rate 1.0 mL/min) or a Cosmosil 5C18-AR-II preparative 
column (Nacalai Tesque, 20 × 250 mm, flow rate 10.0 mL/min) 
was employed, and eluting products were detected by UV at 220 
nm. A solvent system consisting of 0.1% (v/v) TFA in H2O 
(solvent A) and 0.1% (v/v) TFA in MeCN (solvent B) was used 
for HPLC elution. UV-irradiation was performed using a Moritex 
MUV-202U (3000 mW/cm2 HgeXe lamp) with the filtered 
output (>365 nm) and the irradiation power was adjusted to one 
third of the maximum. 
4.2. Preparation of caged non-hydrolyzable phosphoamino 
acid derivatives 
4 .2 .1 .  Allyl  es ters  5a -c  
Typical procedure for preparation of 5a: Potassium carbonate 
(121 mg, 0.880 mmol) and allyl bromide (76 μL, 0.880 mmol) 
were added to a solution of carboxylic acid 4a4a (300 mg, 0.800 
mmol) in DMF (4.0 mL). The resulting mixture was stirred at 
room temperature overnight and was quenched by the addition of 
water. The mixture was extracted with Et2O. The obtained 
organic layer was washed with brine, dried over MgSO4, and 
concentrated in vacuo. The resulting crude product was purified 
by column chromatography (hexanes/EtOAc = 4/1 (v/v)) and 316 
mg of allyl ester 5a (0.760 mmol, 94%) was obtained as a pale 
yellow oil. 
4.2 .1 .1 .  (S )-Al ly l  2 -{ ( tert -butoxycarbonyl)amino}-
4-(die thoxyphosphoryl ) -4 ,4-dif luorobutanoate 
(5a)  
Pale yellow oil; 316 mg; 94% yield; [α]19D 0.03 (c 1.0, 
CHCl3); 1H NMR (CDCl3, 400 MHz) δ = 1.38 (6H, t, J = 7.2 Hz), 
1.44 (9H, s), 2.53-2.80 (2H, m), 4.27 (4H, q, J = 7.2 Hz), 4.58-
4.63 (1H, br m), 4.65 (2H, d, J = 6.0 Hz), 5.26 (1H, d, J = 10.4 
Hz), 5.34 (1H, d, J = 16.4 Hz), 5.90 (1H, ddt, J = 16.4, 10.4 and 
6.0 Hz); 13C NMR (CDCl3, 75 MHz) δ = 16.2 (d, J = 5.4 Hz), 
28.2, 35.2 (td, J = 19.5 and 15.4 Hz), 48.4, 64.7 (d, J = 7.0 Hz), 
66.3, 80.1, 118.8, 131.1, 154.9, 170.6; 31P NMR (CDCl3, 162 
MHz) δ = –5.82 (t, J = 105.7 Hz); HRMS (ESI-TOF) m/z calcd 
for C16H28F2NNaO7P ([M + Na]+) 438.1469, found 438.1479. 
4.2 .1 .2 .  (2S ,3R ) -Al ly l  2 -{ ( tert -
butoxycarbonyl )amino}-4-(die thoxyphosphoryl ) -
4 ,4-dif luoro-3-methylbutanoate (5b)  
Preparation of substrate 4b, see reference 5a. Na2CO3 was 
used instead of K2CO3; colorless oil; 11.3 mg; 98% yield; [α]27D 
17.5 (c 2.0, CHCl3); 1H NMR (CDCl3, 400 MHz) δ =1.30 (3H, d, 
J = 7.2 Hz), 1.37 (6H, t, J = 7.0 Hz), 1.45 (9H, s), 3.13 (1H, m), 
4.26 (4H, m), 4.54 (1H, dd, J = 9.8 and 3.4 Hz), 4.63 (2H, ddd, J 
= 5.9, 1.5 and 1.5 Hz), 5.24 (1H, ddt, J = 11.7, 1.5 and 1.5 Hz), 
5.34 (1H, ddt, J = 17.2, 1.5 and 1.5 Hz), 5.44 (1H, d, J = 9.8 Hz), 
5.90 (1H, ddt, J = 17.2, 11.7 and 5.9 Hz); 13C NMR (CDCl3, 75 
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MHz) δ =12.0 (m), 16.3 (d, J = 1.2 Hz), 16.4 (d, J = 1.2 Hz), 28.3, 
40.2 (m), 54.6 (m), 64.8 (m), 66.2, 80.1, 118.7, 131.6, 156.0, 
170.6; 31P NMR (CDCl3, 162 MHz) δ = 5.54 (dd, J = 109.6 and 
104.1 Hz); HRMS (ESI-TOF) m/z calcd for C17H30F2NNaO7P 
([M + Na]+) 452.1626, found 452.1614. 
4.2 .1 .3 .  (S )-Al ly l  2 -{ ( tert -butoxycarbonyl)amino}-
3-[4 -{ (die thoxyphosphoryl)d if luoromethyl} -
phenyl ]propanoate (5c)  
Preparation of substrate 4c, see reference 6a; Colorless oil; 
263 mg; 85% yield; [α]27D –5.06 (c 1.4, MeOH); 1H NMR 
(CDCl3, 400 MHz) δ = 1.31 (6H, t, J = 7.2 Hz), 1.42 (9H, s), 3.10 
(1H, dd, J = 18.2 and 7.6 Hz), 3.19 (1H, dd, J = 18.2 and 7.2 Hz), 
4.07-4.32 (4H, m), 4.59 (2H, d, J = 5.7 Hz), 4.62 (1H, m), 5.02 
(1H, d, J = 7.5 Hz), 5.25 (1H, d, J = 8.1 Hz), 5.30 (1H, d, J = 
17.3 Hz), 5.85 (1H, ddt, J = 17.3, 8.1 and 5.7 Hz), 7.23 (2H, d, J 
= 8.1 Hz), 7.55 (2H, d, J = 8.1 Hz); 13C NMR (CDCl3, 75 MHz) δ 
= 16.1 (d, J = 5.0 Hz), 28.0, 37.8, 54.1, 64.5 (d, J = 6.2 Hz), 65.8, 
79.7, 117.8 (td, J = 259.6 and 216.3 Hz), 118.8, 126.1, 129.3, 
131.1 (m), 131.2, 139.1, 154.8, 171.0; 31P NMR (CDCl3, 162 
MHz) δ = –6.32 (t, J = 115.6 Hz); HRMS (ESI-TOF) m/z calcd 
for C22H32F2KNO7P ([M + K]+) 530.1522, found 530.1526. 
4.2 .2 .  Fmoc deriva tives  6a-c  
Typical procedure for preparation of 6a: To allyl ester 5a (313 
mg, 0.760 mmol) was added TFA (6.0 mL) with stirring at room 
temperature for 2 h. The mixture was concentrated in vacuo, and 
the residue was dissolved in MeCN/10% (w/v) Na2CO3 aq. (2/1 
(v/v), 14 mL). To the solution was added FmocOSu (279 mg, 
0.828 mmol) and the reaction mixture was stirred at room 
temperature overnight. After addition of 5% (w/v) KHSO4 aq., 
the mixture was extracted with EtOAc. The organic layer was 
washed with brine, dried over MgSO4, and concentrated in vacuo. 
The obtained crude material was purified by column 
chromatography (hexanes/EtOAc = 4/1 (v/v)) and 311 mg of 
Fmoc derivative 6a (0.579 mmol, 77 %) was obtained as a 
colorless oil. 
4.2 .2 .1 .  (S )-Al ly l  2 -( [{(9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-4 -
(die thoxyphosphoryl )-4 ,4-dif luorobutanoate (6a)  
Colorless oil; 311 mg; 77% yield; [α]19D 3.10 (c 0.86, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ = 1.38 (6H, td, J = 7.1 and 2.2 Hz), 
2.58-2.82 (2H, m), 4.20-4.32 (5H, m), 4.37 (2H, d, J = 7.1 Hz), 
4.67 (2H, d, J = 5.4 Hz), 4.65-4.78 (1H, m), 5.26 (1H, dd, J = 
10.5 and 1.2 Hz), 5.35 (1H, dd, J = 17.3 and 1.2 Hz), 5.76 (1H, d, 
J = 8.3 Hz), 5.91 (1H, ddt, J = 17.3, 10.5 and 5.4 Hz), 7.31 (2H, 
td, J = 7.3 and 1.2 Hz), 7.40 (2H, t, J = 7.3 Hz), 7.60 (2H, m), 
7.76 (2H, d, J = 7.3 Hz); 13C NMR (CDCl3, 75 MHz) δ = 16.3 (d, 
J = 5.6 Hz), 35.5 (d, J = 16.2 Hz), 47.0, 48.9, 64.9 (dt, J = 6.2 
and 3.7 Hz), 66.6, 67.4, 119.1, 119.9, 125.1, 127.1, 127.7, 131.3, 
141.2, 143.7, 155.6, 170.3; 31P NMR (CDCl3, 162 MHz) δ = –
5.76 (t, J = 104.7 Hz); HRMS (ESI-TOF) m/z calcd for 
C26H30F2NNaO7P ([M + Na]+) 560.1626, found 560.1628. 
4.2 .2 .2 .  (2S ,3R ) -Al ly l  2 -( [{(9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-4 -
(die thoxyphosphoryl )-4 ,4-dif luoro-3-
methylbutanoate (6b)  
Colorless oil; 137 mg; 97% yield; [α]23D 12.0 (c 2.91, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ = 1.35 (3H, d, J = 7.4 Hz), 1.42 
(6H, td, J = 7.1 and 2.7 Hz), 3.21 (1H, m), 4.23-4.60 (7H, m), 
4.61-4.74 (3H, m), 5.28 (1H, dd, J = 10.4 and 1.2 Hz), 5.38 (1H, 
dd, J = 17.2 and 1.2 Hz), 5.94 (1H, ddt, J = 17.2, 10.4 and 5.8 
Hz), 6.01 (1H, d, J = 9.8 Hz), 7.33 (1H, t, J = 7.5 Hz), 7.34 (1H, t, 
J = 7.5 Hz), 7.42 (2H, t, J = 7.5 Hz), 7.64 (1H, d, J = 7.5 Hz), 
7.66 (1H, d, J = 7.5 Hz), 7.79 (2H, d, J = 7.5 Hz); 13C NMR 
(CDCl3, 75 MHz) δ = 12.1 (t, J = 9.8 Hz), 16.3, 16.4, 40.5 (m), 
47.1, 55.0 (m), 64.8 (d, J = 7.5 Hz), 65.0 (d, J = 6.8 Hz), 66.3, 
67.4, 118.9, 119.9, 125.2, 125.2, 127.0, 127.1, 127.7, 127.7, 
131.5, 141.3, 143.7, 143.9, 156.6, 170.2; 31P NMR (CDCl3, 162 
MHz) δ = 5.51 (dd, J = 109.2 and 103.5 Hz); HRMS (ESI-TOF) 
m/z calcd for C27H32F2NNaO7P ([M + Na]+) 574.1782, found 
574.1786. 
4.2 .2 .3 .  (S )-Al ly l  2 -( [{(9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-3 - [4-
{(die thoxyphosphoryl ) -
dif luoromethyl}phenyl ]propanoate  (6c)  
Colorless oil; 518 mg; 55% yield; [α]27D –7.58 (c 1.0, MeOH); 
1H NMR (CDCl3, 400 MHz) δ = 1.30 (6H, t, J = 7.1 Hz), 3.15 
(1H, dd, J = 14.0 and 5.8 Hz), 3.20 (1H, dd, J = 14.0 and 5.8 Hz), 
4.10-4.25 (5H, m), 4.38 (1H, dd, J = 10.5 and 7.1 Hz), 4.45 (1H, 
dd, J = 10.5 and 7.1 Hz), 4.64 (2H, d, J = 5.9 Hz), 4.70 (1H, dt, J 
= 8.0 and 5.8 Hz), 5.27 (1H, d, J = 11.2 Hz), 5.83 (1H, d, J = 
17.6 Hz), 5.85 (1H, ddt, J = 17.6, 11.2 and 5.9 Hz), 7.20 (2H, d, J 
= 8.1 Hz), 7.32 (2H, t, J = 7.4 Hz), 7.41 (2H, t, J = 7.4 Hz), 7.55 
(2H, d, J = 8.1 Hz), 7.57 (2H, d, J = 7.4 Hz), 7.72 (2H, d, J = 7.4 
Hz); 13C NMR (CDCl3, 75 MHz) δ = 16.3 (d, J = 6.9 Hz), 37.9, 
47.1, 54.7, 64.8 (d, J = 6.9 Hz), 66.2, 66.9, 119.3, 120.0, 125.0 (d, 
J = 4.4 Hz), 126.5 (td, J = 22.0 and 14.4 Hz), 127.1, 127.8, 129.5, 
1310, 131.4 (td, J = 21.8 and 13.7 Hz), 139.0, 141.3, 143.7, 143.8, 
155.6, 170.1; 31P NMR (CDCl3, 162 MHz) δ = –6.35 (t, J = 115.8 
Hz); HRMS (ESI-TOF) m/z calcd for C32H35F2NO7P ([M + H]+) 
614.2119, found 614.2128. 
4.2 .3 .  Phosphonates  7a -c  
Typical procedure for preparation of 7a: Trimethylsilyl 
bromide (22 mL, 163 mmol) was added to a solution of diethyl 
ester 6a (4.39 g, 8.17 mmol) in CH2Cl2 (162 mL), and the 
mixture was stirred at room temperature for 14 h. The reaction 
progress was monitored using 31P NMR. After addition of 
H2O/MeCN, the mixture was concentrated in vacuo. The crude 
material was purified by reprecipitation from hexanes and 3.39 g 
of phosphonate 7a (7.04 mmol, 86%) was obtained as a white 
solid. 
4.2 .3 .1 .  (S )- {3 -( [{(9H -Fluoren-9 -
yl)methoxy}carbonyl ]amino)-4 - (a l ly loxy)-1 ,1-
dif luoro-4 -oxobutyl}phosphonic ac id (7a )  
White solid; 3.39 g; 86% yield; [α]27D –16.3 (c 0.90, MeOH); 
1H NMR (methanol-d4, 400 MHz) δ = 2.46-2.85 (2H, m), 4.23 
(1H, t, J = 7.1 Hz), 4.31 (2H, d, J = 7.1 Hz), 4.64 (2H, d, J = 5.6 
Hz), 4.63-4.81 (1H, m), 5.20 (2H, dd, J = 10.5 and 1.3 Hz), 5.32 
(2H, dd, J = 17.9 and 1.3 Hz), 5.93 (1H, ddt, J = 17.9, 10.5 and 
5.6 Hz), 7.30 (2H, td, J = 7.3 and 1.2 Hz), 7.38 (2H, t, J = 7.3 
Hz), 7.66 (2H, d, J = 7.3 Hz), 7.79 (2H, d, J = 7.3 Hz); 13C NMR 
(methanol-d4, 75 MHz) δ = 34.3 (m), 48.2, 48.8, 65.7, 66.7, 117.1, 
119.4, 124.8, 126.7, 127.3, 131.6, 141.0, 143.7, 156.7, 170.9; 31P 
NMR (methanol-d4, 162 MHz) δ = 4.81 (t, J = 102.7 Hz); HRMS 
(ESI-TOF) m/z calcd for C22H22F2NNaO7P ([M + Na]+) 504.1000, 
found 504.0994. 
4.2 .3 .2 .  {(2R ,3S ) -3 -( [{(9H -Fluoren-9-
yl)methoxy}carbonyl ]amino)-4 - (a l ly loxy)-1 ,1-
dif luoro-2 -methyl -4-oxobuty l}phosphonic ac id 
(7b)  
For purification, column chromatography (CHCl3/methanol = 
99/1 (v/v)) was employed instead of reprecipitation; colorless 
oil ; 29 mg; 81% yield; [α]22D 10.1 (c 2.53, MeOH); 1H NMR 
(methanol-d4, 400 MHz) δ = 1.12 (3H, d, J = 6.5 Hz), 2.93 (1H, 
m), 4.15 (1H, m), 4.24 (2H, m), 4.50 (1H, m), 4.54 (2H, d, J = 
5.6 Hz), 5.11 (1H, dd, J = 10.6 and 1.4 Hz), 5.25 (1H, dd, J = 
17.3 and 1.4 Hz), 5.85 (1H, ddt, J = 17.3, 10.6 and 5.9 Hz), 7.21 
(2H, t, J = 7.4 Hz), 7.29 (2H, t, J = 7.4 Hz), 7.58 (1H, d, J = 7.4 
Hz), 7.60 (1H, d, J = 7.4 Hz), 7.70 (2H, d, J = 7.4 Hz); 13C NMR 
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(methanol-d4, 75 MHz) δ = 12.4 (t, J = 8.6 Hz), 41.6 (m), 48.3, 
56.0 (t, J = 12.4 Hz), 67.0, 68.3, 118.8, 120.9, 126.3, 126.3, 
128.2, 128.8, 133.2, 142.5, 145.1, 145.2, 158.6, 171.9; 31P NMR 
(methanol-d4, 162 MHz) δ = 4.50 (d, J = 103.2 Hz); HRMS (ESI-
TOF) m/z calcd for C23H23F2NO7P ([M – H]–) 494.1180, found 
494.1180. 
4.2 .3 .3 .  (S )- ( [4-{2 -( [{(9H -Fluoren-9 -
yl)methoxy}carbonyl ]amino)-3 - (a l ly loxy)-3-
oxopropyl}-phenyl ]d if luoromethyl )phosphonic 
acid (7c)  
White powder; 465 mg; 52% yield; [α]27D –4.30 (c 1.6, 
MeOH); 1H NMR (methanol-d4, 400 MHz) δ = 3.02 (1H, dd, J = 
13.7 and 9.3 Hz), 3.21 (1H, dd, J = 13.7 and 5.0 Hz), 4.14 (1H, t, 
J = 6.5 Hz), 4.29 (2H, t, J = 6.5 Hz), 4.49 (1H, dd, J = 9.3 and 
5.0 Hz), 4.60 (2H, d, J = 5.5 Hz), 5.20 (1H, d, J =10.7 Hz), 5.29 
(1H, d, J = 17.3 Hz), 5.88 (1H, ddt, J = 17.3, 10.7 and 5.5 Hz), 
7.25-7.40 (6H, m), 7.57 (2H, t, J = 8.2 Hz), 7.59 (2H, d, J = 7.5 
Hz), 7.76 (2H, d, J = 7.5 Hz); 13C NMR (methanol-d4, 75 MHz) δ 
= 38.1, 48.2, 56.7, 66.8, 67.9, 118.8, 119.8 (td, J = 260.3 and 
211.8 Hz), 120.9, 126.1, 127.5 (t, J = 6.2 Hz), 128.1, 128.7, 
130.2, 133.0, 133.6 (td, J = 22.4 and 13.1 Hz), 140.1, 142.5, 1450, 
145.0, 158.2, 172.8; 31P NMR (methanol-d4, 162 MHz) δ = -4.9 (t, 
J = 113.7 Hz); HRMS (ESI-TOF) m/z calcd for C28H26F2KNO7P 
([M + K]+) 596.1052, found 596.1051. 
4.2 .4 .  o -Ni trobenzyl  es ters  8a  and 8c  
Typical procedure for preparation of 8a: To a solution of 
phosphonate 7a (50.0 mg, 104 μmmol) in DMF (520 μL), 
pyridine (20 μL) and p-toluenesulfonyl chloride (99.2 mg, 520 
μmol) were added. After stirring at room temperature for 15 min 
followed by addition of o-nitrobenzyl alcohol (79.5 mg, 519 
μmol), the reaction mixture was stirred at room temperature for 
additional 26 h. The crude material was concentrated in vacuo, 
and the obtained mixture was purified by column 
chromatography (CHCl3/MeOH = 49/1 (v/v)). o-Nitrobenzyl 
ester 8a (43.7 mg, 70.9 μmol, 68%) was obtained as a colorless 
oil. 
4.2 .4 .1 .  (2S )-Al ly l  2 -( [{ (9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-4 ,4 -d if luoro-4 -
[hydroxy-{(2 -
nitrobenzy l)oxy}phosphoryl]butanoate (8a)  
Colorless oil; 43.7 mg; 68% yield; [α]27D –7.43 (c 0.92, 
MeOH); 1H NMR (methanol-d4, 400 MHz) δ = 2.35-2.77 (2H, m), 
4.10 (1H, t, J = 7.1 Hz), 4.18-4.21 (2H, m), 4.50-4.59 (3H, m), 
5.14 (1H, dt, J = 10.5 and 1.4 Hz), 5.23 (1H, dt, J = 17.2 and 1.4 
Hz), 5.37 (2H, d, J = 7.0 Hz), 5.82 (1H, ddt, J = 17.2, 10.5 and 
5.6 Hz), 7.20 (2H, t, J = 7.5 Hz), 7.28 (2H, t, J = 7.5 Hz), 7.38 
(1H, t, J = 7.8 Hz), 7.57 (2H, d, J = 7.5 Hz), 7.61 (1H, dd, J = 7.8 
and 7.5 Hz), 7.68 (2H, d, J = 7.5 Hz), 7.89 (1H, d, J = 7.8 Hz), 
8.00 (1H, d, J = 7.5 Hz); 31P NMR (methanol-d4, 162 MHz) δ = 
3.58 (t, J = 90.7 Hz); HRMS (ESI-TOF) m/z calcd for 
C29H26F2N2O9P ([M – H]–) 615.1344, found 615.1346. Because 
time dependent decomposition of 8a was observed, it was used 
without hesitation for a subsequent reaction after measurement of 
1H and 31P NMR followed by HRMS and optical rotation. In this 
experiment, time-consuming 13C NMR was not recorded. 
4.2 .4 .2 .  (2S )-Al ly l  2 -( [{ (9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-3 -{4 -
(dif luoro[hydroxy{(2 -
nitrobenzy l)oxy}phosphoryl]methyl )phenyl}propa
noate  (8c)  
White powder; 42.0 mg; 54% yield; [α]27D –6.10 (c 0.76, 
MeOH); 1H NMR (methanol-d4, 400 MHz) δ = 3.01 (1H, dd, J = 
14.0 and 9.2 Hz), 3.20 (1H, dd, J = 14.0 and 5.1 Hz), 4.15 (1H, t, 
J = 6.9 Hz), 4.29 (2H, d, J = 6.9 Hz), 4.49 (1H, dd, J = 9.2 and 
5.1 Hz), 4.62 (2H, d, J = 5.6 Hz), 5.21 (1H, ddt, J = 10.5, 1.4 and 
1.1 Hz), 5.28-5.37 (3H, m), 5.91 (1H, ddt, J = 16.9, 10.5 and 5.6 
Hz), 7.22-7.34 (4H, m), 7.47 (1H, t, J = 7.9 Hz), 7.54-7.64 (4H, 
m), 7.68 (1H, t, J = 7.7 Hz), 7.78 (2H, d, J = 7.6 Hz), 7.96 (1H, d, 
J = 7.7 Hz), 8.06 (1H, d, J = 7.9 Hz); 13C NMR (pyridine-d5, 75 
MHz) δ =37.4, 47.3, 55.9, 65.3 (d, J = 9.1 Hz), 65.4, 66.3, 118.0, 
120.0, 124.4, 125.2, 125.2, 126.8 (br m), 127.1, 127.7, 127.8, 
128.7, 129.0, 132.1, 133.7, 139.1, 141.3, 114.0, 144.1, 146.7, 
156.7, 171.7; 31P NMR (pyridine-d5, 162 MHz) δ = 4.44 (t, J 
=98.1 Hz); HRMS (ESI-TOF) m/z calcd for C35H30F2N2O9P ([M 
– H]–) 691.1657, found 691.1656. 
4.2 .5 .  o -Ni trobenzyl  es ters  8b  
To a solution of phosphonate 7b (24.8 mg, 50.1 μmmol) in 
DMF (500 μL) were added o-nitrobenzyl bromide (43.0 mg, 200 
μmol) and DIEA (19.1 μL, 110 μmol). After stirring at 50 ˚C for 
3 h, the mixture was concentrated in vacuo. Following to 
purification of the obtained crude material by column 
chromatography (CHCl3/MeOH = 49/1 (v/v)), o-nitrobenzyl ester 
8b (26.6 mg, 42.2 μmol, 84%) was obtained as a white powder. 
4.2 .5 .1 .  (2S ,3R ) -Al ly l  2 -( [{(9H -f luoren-9 -
yl)methoxy}carbonyl ]amino)-4 ,4 -d if luoro-4 -
[hydroxy{(2-ni tro -benzy l)oxy}phosphoryl ] -3-
methylbutanoate (8b)  
[α]16D 4.22 (c 1.2, MeOH); 1H NMR (methanol-d4, 400 MHz) 
δ = 1.24 (3H, d, J = 7.2 Hz), 4.08-4.18 (1H, m), 4.19-4.23 (2H, 
m), 4.44 (1H, m), 4.53 (2H, m), 5.09 (1H, ddt, J = 10.6, 1.4 and 
1.4 Hz), 5.24 (1H, ddt, J = 17.2, 1.4 and 1.4 Hz), 5.37 (2H, d, J = 
7.1 Hz), 5.83 (1H, ddt, J = 17.2, 10.6 and 5.8 Hz), 7.20 (2H, t, J 
= 7.6 Hz), 7.28 (2H, t, J = 7.6 Hz), 7.40 (1H, t, J = 7.7 Hz), 7.56-
7.66 (3H, m), 7.69 (2H, d, J = 7.6 Hz), 7.92 (1H, d, J = 7.7 Hz), 
8.02 (1H, d, J = 8.1 Hz); 31P NMR (methanol-d4, 162 MHz) δ = 
2.91 (t, J =91.5 Hz); HRMS (ESI-TOF) m/z calcd for 
C30H28F2N2O9P ([M – H]–) 629.1501, found 629.1491. Because 
time dependent decomposition of 8b was observed, it was used 
without hesitation for a subsequent reaction after measurement of 
1H and 31P NMR followed by HRMS and optical rotation. In this 
experiment, time-consuming 13C NMR was not recorded. 
4.2 .6 .  Non-hydrolyzable amino  acid deriva tives  
3a-c  
Typical procedure for preparation of 3a: N-Methylaniline (241 
mg, 2.24 mmol) and (Ph3P)4Pd (25.9 mg, 22.4 μmol) were added 
to a solution of allyl ester 8a (138 mg, 224 μmol) in THF (4.48 
mL), and the resulting mixture was stirred at room temperature 
for 4 h. After addition of 1 M HCl aq., the mixture was extracted 
with CH2Cl2. The organic layer was washed with water followed 
by brine, dried over Na2SO4, and concentrated in vacuo. The 
obtained crude material was used to a subsequent reaction 
without further purification. 
4.2 .6 .1 .  (2S )-2 - ([{ (9H -Fluoren-9 -
yl)methoxy}carbonyl ]amino)-4 ,4 -d if luoro-4 -
[hydroxy{(2-
nitrobenzy l)oxy}phosphoryl]butanoic  ac id (3a)  
White powder; 123 mg; HRMS (ESI-TOF) m/z calcd for 
C26H23F2N2NaO9P ([M + Na]+) 599.1007, found 599.0990. 
4.2 .6 .2 .  (2S ,3R ) -2- ( [{ (9H-Fluoren-9 -
yl)methoxy}carbonyl ]amino)-4 ,4 -d if luoro-4 -
[hydroxy{(2-ni trobenzyl )oxy}phosphoryl ] -3-
methylbutanoic  acid (3b)  
White powder; 26.2 mg; HRMS (ESI-TOF) m/z calcd for 
C27H24F2N2O9P ([M – H]–) 589.1188, found 589.1184. 
4.2 .6 .3 .  (2S )-2 - ([{ (9H -Fluoren-9 -
yl)methoxy}carbonyl ]amino)-3 -{4 -
(dif luoro[hydroxy{(2 -ni tro-
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benzyl )oxy}phosphoryl ]methyl )pheny l}propanoic 
acid (3c)  
White powder; 53.0 mg; HRMS (ESI-TOF) m/z calcd for 
C32H28F2N2O9P ([M + H]+) 653.1501, found 653.1487. 
4.3. Preparation of caged peptides 9a-c 
Typical procedure for preparation of 9a: On NovaSyn® TGR 
resin (loading: 0.22 mmol/g, 30 mg, 6.6 μmol) were coupled 
Fmoc protected amino acids (3.0 eq.) in the presence of O-
(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HBTU, 2.9 eq.) and N,N-
diisopropylethyamine (DIEA, 2.9 eq.) in DMF at room 
temperature for 0.5 h before coupling of the caged amino acid. 
Incorporation of crude 3a (7.6 mg, <2.0 eq.) was achieved by the 
use of 2-(1H-7-azabenzotriaol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU, 1.95 eq.) in the presence of DIEA 
(4.0 eq.) and 1-hydroxyl-7-azabenzotriazole (HOAt, 2.2 eq.) in 
DMF at room temperature for 4 h. After acetyl capping (10 eq. of 
acetic anhydride and 10 eq. of pyridine in DMF, 0.5 h at room 
temperature), following couplings were performed for elongation 
of a peptide using an Fmoc protected amino acid (5.0 eq.), HBTU 
(4.5 eq.) and DIEA (10 eq.) in DMF at room temperature for 1 h. 
Then Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-miniPEG-
OH, 3.0 eq.) was incorporated using HBTU (2.9 eq.) and DIEA 
(2.9 eq.) in DMF for 1 h at room temperature. After removal of 
N-terminal Fmoc group of the miniPEG, the resin was reacted 
with fluorescein isomer I (FITC, 2.5 eq.) and DIEA (2.5 eq.) in 
DMF for 1 h twice. The resulted complete resin was treated with 
TFA/m-cresol/thioanisole/triethylsilane/H2O (80/5/5/5/5 (v/v)) at 
room temperature for 2 h. After the resin was filtered off, cooled 
diethyl ether was added to the filtrate, and the resulting 
precipitate was collected by centrifugation. The obtained 
precipitate was washed with diethyl ether and purified by 
preparative HPLC to give caged peptide 9a (4.6 mg, 44%) as a 
yellowish lyophilized powder. Analytical HPLC conditions: a 
linear gradient of solvent B in solvent A over 30 min. Preparative 
HPLC conditions: a linear gradient of solvent B in solvent A over 
30 min. 
4.3 .1 .  Pept ide  9a  
Yellow lyophilized powder; 4.60 mg; 44% yield; Analytical 
HPLC conditions: 10 to 45% over 30 min. Retention time = 27.2 
min; Preparative HPLC conditions: 10 to 35% over 50 min; 
LRMS (ESI-TOF) m/z calcd for [M + H]+ 1586.6, found; 1586.7. 
4.3 .2 .  Pept ide  9b  
White lyophilized powder; 0.21 mg; 3% yield; Analytical 
HPLC conditions: 5 to 45% over 30 min. Retention time = 21.8 
min; Preparative HPLC conditions: 15 to 35% over 30 min; 
LRMS (ESI-TOF) m/z calcd for [M + H]+ 1066.5, found; 1066.1. 
4.3 .3 .  Pept ide  9c  
white lyophilized powder; 1.12 mg; 15% yield; Analytical 
HPLC conditions: 5 to 45% over 30 min. Retention time = 24.2 
min; Preparative HPLC conditions: 15 to 35% over 30 min; 
LRMS (ESI-TOF) m/z calcd for [M + H]+ 1128.5, found; 1128.1. 
4.4. Modified preparation of threonine derivative 4b 
 
Scheme 4. Preparation of synthetic intermediate 13. Reagents and conditions: 
a) tetrabutylammonium azide, MeCN, 0 °C, 51%. 
 
To a solution of substrate 125a (230 mg, 0.51 mmol) in 
acetonitrile (1.7 mL) was added tetrabutylammonium azide (440 
mg, 1.6 mmol), and the reaction mixture was stirred at 0 °C for 
12 h. After addition of water, the mixture was extracted with 
Et2O. The obtained organic layer was washed with brine, dried 
over MgSO4, and concentrated in vacuo. The resulting crude 
product was purified by column chromatography 
(hexanes/EtOAc = 4/1 (v/v)) and 110 mg of azide 13 (0.26 mmol, 
51%) was obtained as a pale yellow oil. 1H NMR spectrum was 
identical with that reported previously.5a 
4.5. UV-irradiation experiment of peptide 9a-c 
Typical procedure for caged peptide 9a: Peptide 9a (50 μg, 
0.032 μmol) in sodium phosphate buffer (10 mM phosphate, pH 
7.6, 500 μL) was irradiated by UV (>365 nm; irradiation power: 
one third of the maximum) for 7 min. Progress of the reaction 
was monitored by analytical HPLC and uncaged product 10a’ 
was characterized using ESI-MS. Analytical HPLC conditions: a 
linear gradient of solvent B in solvent A over 30 min. 
4.5 .1 .  Pept ide  10a’  
Analytical HPLC conditions: 10 to 45% over 30 min. 
Retention time = 21.8 min; LRMS (ESI-TOF) m/z calcd for [M + 
H]+ 1435.6, found; 1434.8. 
4.5 .2 .  Pept ide  10a 
Analytical HPLC conditions: 10 to 45% over 30 min. 
Retention time = 23.3 min; LRMS (ESI-TOF) m/z calcd for [M + 
2H]2+ 726.3, found; 726.1. As the reaction solvent, 1% (v/v) TFA 
in water was used instead of the phosphate buffer. 
4.5 .3 .  Pept ide  10b  
Analytical HPLC conditions: 5 to 45% over 30 min. Retention 
time = 14.5 min; LRMS (ESI-TOF) m/z calcd for [M + H]+ 931.4, 
found; 931.2. 
4.5 .4 .  Pept ide  10c  
Analytical HPLC conditions: 5 to 45% over 30 min. Retention 
time = 17.8 min; LRMS (ESI-TOF) m/z calcd for [M + H]+ 993.5, 
found; 993.2. 
4.6. Preparation of control peptides 10a and 11 
Peptides 10a and 11 were prepared as similar to the caged 
peptides. For construction of peptide 11 and a synthetic 
intermediate of 10a before introduction of a non-hydrolyzable 
phosphoserine unit, N,N’-diisopropylcarbodiimide (DIC)/HOBt 
system was employed (3.0 eq. amino acid, 3.2 eq. DIC, 3.0 eq. 
HOBt·H2O in DMF, 2 h at room temperature). Coupling of 
phosphoserine mimic 144a,16b was achieved using 
HATU/HOAt/DIEA system (3 eq. 14, 2.9 eq. HATU, 2.9 eq. 
HOAt, 8.7 eq. DIEA in DMF, 1 h at room temperature). 
Elongation of following amino acids was performed using the 
DIC/HOBt and/or the HATU/HOAt/DIEA system. 
 
 
Figure 3. Structure of phosphoserine mimic 14. 
 
4.6 .1 .  Pept ide  10a 
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Yellow lyophilized powder; 2.39 mg; 14% yield; Analytical 
HPLC conditions: 20 to 40% over 30 min. Retention time = 18.9 
min; Preparative HPLC conditions: 10 to 35% over 45 min; 
LRMS (ESI-TOF) m/z calcd for [M + 2H]2+ 726.3, found; 726.2. 
4.6 .2 .  Pept ide  11  
Yellow lyophilized powder; 2.20 mg; 8% yield; Analytical 
HPLC conditions: 20 to 40% over 30 min. Retention time = 18.6 
min; Preparative HPLC conditions: 10 to 35% over 45 min; 
LRMS (ESI-TOF) m/z calcd for [M + H]+ 1337.6, found; 1336.9. 
4.7. Binding assay using FP 
Typical procedure: caged peptide 9a (20 nM final) in HEPES 
buffer [10 mM HEPES, 150 mM NaCl, 0.05% (w/v) Tween-20, 
0.5 mM dithiothreitol, pH 7.4, 50 μL]22 was incubated at 20 ˚C in 
the absence or presence of 14-3-3β protein (500 nM, final) for 1 
h.17 After recording the FP response in mP (milli-polarization 
units), ΔmP values were calculated as follows: ΔmP = (FP in the 
presence of 14-3-3β) – (FP in the absence of 14-3-3β). Averages 
of nine measurements with the standard error of the mean are 
shown in Figure 2. For the photo-irradiation experiments, peptide 
9a in HEPES buffer was subjected to UV irradiation (>365 nm; 
irradiation power: one third of the maximum) for 7 min before 
the FP experiments. Completion of the uncaging reaction was 
confirmed by HPLC monitoring. 
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